Whole Foods 2008 Annual Report Download - page 32

Download and view the complete annual report

Please find page 32 of the 2008 Whole Foods annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 88

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88

26
The following table summarizes information about our Company’s equity compensation plans by type as of September 28,
2008 (in thousands, except per share amounts):
Options
Weighted Available
Options Average for Future
Plan Category Outstanding Exercise Price Issuance
Approved by security holders 17,430 $48.64 4,537
Not approved by security holders - - -
Total 17,430 $48.64 4,537
On November 5, 2008, the Company announced an agreement to sell Series A Preferred Stock due 2020 to Green Equity
Investors V, L.P., an affiliate of Leonard Green & Partners, L.P., for $425 million. At the time of the announcement, this
equated to an ownership interest, assuming conversion of the preferred stock to common stock, in the Company of
approximately 17%. The preferred stock has an 8% dividend, payable quarterly in cash or by increasing the liquidation
preference, and is convertible under certain circumstances to common stock at an initial conversion price of $14.50 per share.
The closing and funding of the transaction is subject to certain customary closing conditions, including the receipt of
customary regulatory approvals. There can be no assurance that these approvals will be received.